👉👉As we are increasingly using NGS MRD (10-6 sensitivity) vs. flow (10-4 sensitivity) such as in B-ALL, here is a brief summary slide with some general concepts about assay depth, and blood vs marrow as sample source

Welcome additional thoughts and comments.

Looks like we may have another preventative COVID mAb soon 🤔 - excited to see full data set!

astrazeneca-us.com/media/press-re…

Excited to see this presentation Nitin Jain 😄

Great start to the morning for the #MDEducation CLL/Lymphoma meeting! #cllsm Matthew Davids, MD, MMSc Adam Kittai

I think one of the hardest things about trying to do “team-based” outpatient medicine is how hard it is to get a hold of outside docs sometimes… anyway feeling very thankful this morning with an exceptional communicator to help with care of a complex pt together 😄 #MedTwitter

Women are amazing #MedTwitter

This is great 👏🏻

“It just smells illegal” chadi nabhan MD, MBA, FACP 😂 - great podcast Aaron Goodman - “Papa Heme”

Couldn’t have said better myself. Wise thread by Vincent Rajkumar. #endmoc American Board of Internal Medicine (ABIM) #MedTwitter

Would love to see a larger trial but encouraging results from this small feasibility study: Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy #cllsm ashpublications.org/bloodadvances/…

Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies ashpublications.org/blood/article-…

Taking a break from #AACR24 to watch a (significantly) more athletic C.C. (Caitlyn Clark) Taylor Lab UM Hai Dang Nguyen, PhD

Off to a great start in room 6D - come join to learn more about CH! Kelly Bolton MD PhD #AACR 24 #AACR

🫠 kinda not surprising at all but I gotta say, my own experiences have not been negative with my male colleagues (I might be a bit of a dodgy type with academic “scut work” though)

This 👇🏼 (and yes San Diego is a fickle mistress weather wise…)

Pre-gaming for the clonal hematopoiesis education session tomorrow! #AACR2024 #AACR24

Interesting strategy of CD30 CAR as consolidation after ASCT for high risk Hodgkin, T-cell and grey zone lymphoma (CD30+).

Hard to know what contribution the CAR have to the median PFS of 32 months. #lymsm

thelancet.com/journals/lanha…

As a former chemist-in-training (many don’t know I was in chemistry grad school prior to medicine), was a joy to be interviewed for c&en! #cllsm

Excited about this study and we are now open to accrual at UCI as well!

Well this is exciting news for immunosuppressed patients 👍🏻